Last updated 2026-09-01
Total raised
—
Stage
—
Founded
2013
Headcount
—
HQ
Tel Aviv, Israel
Sector
Biotechnology
Website ↗Registrar ID: 514847805 (MET. SYN. LYSINE LTD)
About
MSL Pharma Ltd. (Met Syn Lysine) focuses on ideation, analysis, and identifying pathological pathways to treat diseases. The company develops novel peptidomimetics for treating obesity and metabolic syndrome (from a pre-diabetic state to type 2 diabetes, dyslipidemia, hypertension). They also have technologies to synthesize novel peptides for peptide-drug conjugates (PDCs) to diagnose and treat different tumors. The company aims to improve and prolong people's lives, reduce morbidity and mortality by relying on evidence-based medicine, analyzing science, and innovating.
Offices
Tel Aviv, Israel · HQ / main office
Q&A
- What is MSL Pharma Ltd. (Met Syn Lysine)'s primary focus?
- MSL Pharma Ltd. (Met Syn Lysine) focuses on developing novel peptidomimetics for treating obesity and metabolic syndrome, including pre-diabetic states, type 2 diabetes, dyslipidemia, and hypertension.
- What additional technologies does MSL Pharma Ltd. (Met Syn Lysine) possess?
- MSL Pharma Ltd. (Met Syn Lysine) also has technologies for synthesizing novel peptides for peptide-drug conjugates (PDCs) aimed at diagnosing and treating various tumors.
- When was MSL Pharma Ltd. (Met Syn Lysine) founded?
- MSL Pharma Ltd. (Met Syn Lysine) was founded in 2013.
- Where is MSL Pharma Ltd. (Met Syn Lysine) headquartered?
- MSL Pharma Ltd. (Met Syn Lysine) is headquartered in Tel Aviv, Israel.
- Who is the founder and CEO of MSL Pharma Ltd. (Met Syn Lysine)?
- Dr. Yarom Cohen is the CEO and Founder of MSL Pharma Ltd. (Met Syn Lysine).
- What are the primary target markets for MSL Pharma Ltd. (Met Syn Lysine)?
- MSL Pharma Ltd. (Met Syn Lysine) targets markets including obesity, metabolic syndrome, diabetes, cancer, Alzheimer's Disease, Parkinson's Disease, Post Traumatic Stress Disorder (PTSD), and Autism.
- What is MSL Pharma Ltd. (Met Syn Lysine)'s core technology?
- MSL Pharma Ltd. (Met Syn Lysine)'s core technology involves peptidomimetics and cyclic peptides.
Sectors & technology
Primary sector
Biotechnology
Technologies
Target customers
Business model
B2C
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | met-syn-lysine.com |
|---|
Identifiers & details
| Legal name | MET. SYN. LYSINE LTD |
|---|---|
| Founded | 2013 |
Radar intelligence
Web history (Wayback)
| Domain | met-syn-lysine.com |
|---|
Certificate / subdomain footprint
| Subdomains | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514847805 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2012-12-24 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 4 — annual_report (3), violation (1) |
| Registered address | הפרגים רמת אפעל 6 רמת גן |
Recent registry events
| Date | Event |
|---|---|
| 2025-09-02 | דו~ח שנתי-עדכון מען דיגיטלי |
| 2025-09-02 | דו~ח שנתי-עדכון תחום עיסוק |
| 2025-09-02 | דו~ח שנתי-שינוי בהוראות בתקנון |
| 2025-09-02 | עדכון הפרה |